Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes
© 2023 by the American Diabetes Association..
Metabolic effects of glucagon-like peptide 1 (GLP-1) receptor agonists are confounded by weight loss and not fully recapitulated by increasing endogenous GLP-1. We tested the hypothesis that GLP-1 receptor (GLP-1R) agonists exert weight loss-independent, GLP-1R-dependent effects that differ from effects of increasing endogenous GLP-1. Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin. The GLP-1R antagonist exendin(9-39) and placebo were administered in a two-by-two crossover study during mixed-meal tests. Liraglutide and diet, but not sitagliptin, caused weight loss. Liraglutide improved insulin sensitivity measured by HOMA for insulin resistance (HOMA-IR), the updated HOMA model (HOMA2), and the Matsuda index after 2 weeks, prior to weight loss. Liraglutide decreased fasting and postprandial glucose levels, and decreased insulin, C-peptide, and fasting glucagon levels. In contrast, diet-induced weight loss improved insulin sensitivity by HOMA-IR and HOMA2, but not the Matsuda index, and did not decrease glucose levels. Sitagliptin increased endogenous GLP-1 and GIP values without altering insulin sensitivity or fasting glucose levels, but decreased postprandial glucose and glucagon levels. Notably, sitagliptin increased GIP without altering weight. Acute GLP-1R antagonism increased glucose levels in all groups, increased the Matsuda index and fasting glucagon level during liraglutide treatment, and increased endogenous GLP-1 values during liraglutide and sitagliptin treatments. Thus, liraglutide exerts rapid, weight loss-independent, GLP-1R-dependent effects on insulin sensitivity that are not achieved by increasing endogenous GLP-1.
ARTICLE HIGHLIGHTS: Metabolic benefits of glucagon-like peptide 1 (GLP-1) receptor agonists are confounded by weight loss and are not fully achieved by increasing endogenous GLP-1 through dipeptidyl peptidase 4 (DPP-4) inhibition. We investigated weight loss-independent, GLP-1 receptor (GLP-1R)-dependent metabolic effects of liraglutide versus a hypocaloric diet or the DPP-4 inhibitor sitagliptin. GLP-1R antagonism with exendin(9-39) was used to assess GLP-1R-dependent effects during mixed meals. Liraglutide improved insulin sensitivity and decreased fasting and postprandial glucose prior to weight loss, and these benefits were reversed by exendin(9-39). GLP-1R agonists exert rapid, weight loss-independent, GLP-1R-dependent effects on insulin sensitivity not achieved by increasing endogenous GLP-1.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
---|---|
Enthalten in: |
Diabetes - 73(2024), 1 vom: 01. Jan., Seite 38-50 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mashayekhi, Mona [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 22.12.2023 Date Revised 20.03.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.2337/db23-0356 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36366923X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM36366923X | ||
003 | DE-627 | ||
005 | 20240320233553.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2337/db23-0356 |2 doi | |
028 | 5 | 2 | |a pubmed24n1337.xml |
035 | |a (DE-627)NLM36366923X | ||
035 | |a (NLM)37874653 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mashayekhi, Mona |e verfasserin |4 aut | |
245 | 1 | 0 | |a Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.12.2023 | ||
500 | |a Date Revised 20.03.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 by the American Diabetes Association. | ||
520 | |a Metabolic effects of glucagon-like peptide 1 (GLP-1) receptor agonists are confounded by weight loss and not fully recapitulated by increasing endogenous GLP-1. We tested the hypothesis that GLP-1 receptor (GLP-1R) agonists exert weight loss-independent, GLP-1R-dependent effects that differ from effects of increasing endogenous GLP-1. Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin. The GLP-1R antagonist exendin(9-39) and placebo were administered in a two-by-two crossover study during mixed-meal tests. Liraglutide and diet, but not sitagliptin, caused weight loss. Liraglutide improved insulin sensitivity measured by HOMA for insulin resistance (HOMA-IR), the updated HOMA model (HOMA2), and the Matsuda index after 2 weeks, prior to weight loss. Liraglutide decreased fasting and postprandial glucose levels, and decreased insulin, C-peptide, and fasting glucagon levels. In contrast, diet-induced weight loss improved insulin sensitivity by HOMA-IR and HOMA2, but not the Matsuda index, and did not decrease glucose levels. Sitagliptin increased endogenous GLP-1 and GIP values without altering insulin sensitivity or fasting glucose levels, but decreased postprandial glucose and glucagon levels. Notably, sitagliptin increased GIP without altering weight. Acute GLP-1R antagonism increased glucose levels in all groups, increased the Matsuda index and fasting glucagon level during liraglutide treatment, and increased endogenous GLP-1 values during liraglutide and sitagliptin treatments. Thus, liraglutide exerts rapid, weight loss-independent, GLP-1R-dependent effects on insulin sensitivity that are not achieved by increasing endogenous GLP-1 | ||
520 | |a ARTICLE HIGHLIGHTS: Metabolic benefits of glucagon-like peptide 1 (GLP-1) receptor agonists are confounded by weight loss and are not fully achieved by increasing endogenous GLP-1 through dipeptidyl peptidase 4 (DPP-4) inhibition. We investigated weight loss-independent, GLP-1 receptor (GLP-1R)-dependent metabolic effects of liraglutide versus a hypocaloric diet or the DPP-4 inhibitor sitagliptin. GLP-1R antagonism with exendin(9-39) was used to assess GLP-1R-dependent effects during mixed meals. Liraglutide improved insulin sensitivity and decreased fasting and postprandial glucose prior to weight loss, and these benefits were reversed by exendin(9-39). GLP-1R agonists exert rapid, weight loss-independent, GLP-1R-dependent effects on insulin sensitivity not achieved by increasing endogenous GLP-1 | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Liraglutide |2 NLM | |
650 | 7 | |a 839I73S42A |2 NLM | |
650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
650 | 7 | |a Dipeptidyl Peptidase 4 |2 NLM | |
650 | 7 | |a EC 3.4.14.5 |2 NLM | |
650 | 7 | |a Glucagon |2 NLM | |
650 | 7 | |a 9007-92-5 |2 NLM | |
650 | 7 | |a Blood Glucose |2 NLM | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Sitagliptin Phosphate |2 NLM | |
650 | 7 | |a TS63EW8X6F |2 NLM | |
650 | 7 | |a Dipeptidyl-Peptidase IV Inhibitors |2 NLM | |
650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
650 | 7 | |a 89750-14-1 |2 NLM | |
700 | 1 | |a Nian, Hui |e verfasserin |4 aut | |
700 | 1 | |a Mayfield, Dustin |e verfasserin |4 aut | |
700 | 1 | |a Devin, Jessica K |e verfasserin |4 aut | |
700 | 1 | |a Gamboa, Jorge L |e verfasserin |4 aut | |
700 | 1 | |a Yu, Chang |e verfasserin |4 aut | |
700 | 1 | |a Silver, Heidi J |e verfasserin |4 aut | |
700 | 1 | |a Niswender, Kevin |e verfasserin |4 aut | |
700 | 1 | |a Luther, James M |e verfasserin |4 aut | |
700 | 1 | |a Brown, Nancy J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetes |d 1952 |g 73(2024), 1 vom: 01. Jan., Seite 38-50 |w (DE-627)NLM000060011 |x 1939-327X |7 nnns |
773 | 1 | 8 | |g volume:73 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:38-50 |
856 | 4 | 0 | |u http://dx.doi.org/10.2337/db23-0356 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 73 |j 2024 |e 1 |b 01 |c 01 |h 38-50 |